Sigma-Aldrich has announced that it has entered an exclusive arrangement with Rosetta Inpharmatics LLC to access the company's proprietary and patent pending bioinformatics design tools for siRNA research and development purposes.
Sigma-Aldrich and Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc., have signed an exclusive license agreement that will provide RNAi researchers with siRNA design technology for enhanced performance through improved specificity and silencing.
Sigma- Aldrich plans to utilize Rosetta Inpharmatics' design technology to launch human and model organism siRNA whole genome libraries, to deliver siRNA panels targeted to specific gene families, and to provide access to single-target pre-designed siRNAs through an enhanced Web interface on Sigma-Aldrich's award-winning Web site.
Researchers will have access to these products that will be manufactured worldwide by its Sigma Genosys and Proligo operations.
"The expertise and recognition Rosetta Inpharmatics has in the area of bioinformatics is world-class," said Shaf Yousaf, President of Sigma-Aldrich's Research Biotechnology Business Unit.
"We are excited to create this powerful relationship and continue our goal of providing cutting-edge tools to enable life science research."
Douglas Bassett, Jr., Executive Director, Informatics at Rosetta Inpharmatics, said, "We are excited to work with Sigma-Aldrich. It offers the opportunity for our most advanced siRNA design technology to be leveraged in the marketplace to provide enhanced knock-down for low expressed genes in concert with reduced off-target effects."